Drug intelligence / Profile preview

CU-20101

Development stage: Phase 3
Lead developer: Cutia Therapeutics
Modality: Recombinant Proteins and Enzymes
Administration: Injection

Overview

CU-20101 is a Botulinum Toxin Type A for injection, developed by Cutia Therapeutics (Wuxi) Co.,Ltd and CKD Bio. It functions by preventing the release of acetylcholine at the neuromuscular junction through the cleavage of SNARE proteins, specifically Synaptosomal-associated protein 25 (SNAP-25), leading to temporary muscle paralysis. It is currently in Phase 3 clinical trials for the treatment of moderate to severe glabellar lines.

Other names: Botulinum Toxin Type a for Injection

Targets

SNAP25 (Synaptosome-associated protein 25)SYT2 (Synaptotagmin-2)

Beyond the preview

Go deeper on CU-20101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CU-20101.

Explore the full profile